Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2012.0240


Dual inhibition of HER2 for a safe increase of efficacy in breast cancer.

Charalabos Batsis, MD.

Affiliation: Charalabos Batsis, Assistant Professor of Surgery, Department of Surgery, University Hospital of Ioannina, Ioannina, TK 45110, Greece.


Since there is no abstract available we provide the first paragraph.
A combination of two anti-HER2 drugs, trastuzumab and lapatinib, can have a synergistic antitumor activity and be more effective than one single drug added to standard chemotherapy for HER2-positive breast cancer patients reports a recent paper in Lancet [1].

(Citation: Gastric & Breast Cancer 2012; 11(3): 160-162)

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 10 July 2012